Science News: Biogen and the FDA
Update: 2021-08-31
Description
This week, Peter Simons covers a BMJ investigation that found the FDA's "accelerated approval" process has left ineffective drugs on the market, some for more than 20 years, without follow-up studies to demonstrate efficacy. He also covers further developments in the FDA and Biogen controversy around Alzheimer's drug aducanumab (Aduhelm).
- FDA’s “Accelerated Approval” Process Leaves Ineffective Drugs on the Market
- Do we all have Alzheimer’s? Drug makers might want you to think so
- Biogen pulled Aduhelm paper after JAMA demanded edits
- Acting FDA Chief Janet Woodcock Ruled Out as Biden Nominee
- Sage Therapeutics axes 2 zuranolone trials deemed unnecessary for approval in depression
Comments
Top Podcasts
The Best New Comedy Podcast Right Now – June 2024The Best News Podcast Right Now – June 2024The Best New Business Podcast Right Now – June 2024The Best New Sports Podcast Right Now – June 2024The Best New True Crime Podcast Right Now – June 2024The Best New Joe Rogan Experience Podcast Right Now – June 20The Best New Dan Bongino Show Podcast Right Now – June 20The Best New Mark Levin Podcast – June 2024
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
